Search Results

MaaT Pharma, a clinical-stage biotechnology company and a leader in the development of Microbiome Ecosystem TherapiesTM dedicated to enhancing survival of patients with cancer, announces the initiation of coverage of its stock by Gilbert Dupont.

DuPont announced that its Board of Directors has declared a third quarter dividend of thirty-six cents per share on the outstanding Common Stock of the Company payable on December 15, 2023, to holders of record of said stock at the close of business on November 30, 2023.

Qosina is pleased to announce it has teamed up with DuPont™ Liveo™ Healthcare Solutions, a leader in the innovative design and production of solutions for biopharmaceutical, pharmaceutical and medical device markets.

NANOBIOTIX, a late-clinical stage biotechnology company pioneering physics-based approaches to expand treatment possibilities for patients with cancer, issued the Half-Year report on its liquidity contract with Gilbert Dupont.

DuPont (NYSE: DD) today announced financial results for the third quarter 2021.

DuPont has launched a new online sales portal tailored to the needs of bioprocessing industry purchasers. The portal handles online sales transactions, with target lead times of < 1 week.

Sofinnova Partners, a leading European life sciences venture capital firm based in Paris, London, and Milan, announced the strategic strengthening of its medtech acceleration team with the appointment of Mano Iyer as Partner and the promotion of Cécile Dupont to Partner.

Vonco Acquires Flex-Pak, Specialty Provider of DuPont™ Tyvek ® , Expanding its Contract Manufacturing Capabilities and Services for Healthcare and Consumer Markets.

Regulatory News: IFF (NYSE: IFF) (Euronext Paris: IFF) (TASE: IFF) and DuPont (NYSE: DD) announced that, during a special meeting held earlier today, IFF shareholders voted to approve the issuance of shares of IFF common stock in connection with the previously announced proposed merger of IFF and DuPont’s Nutrition & Bioscience

Apexigen, Inc. announced the appointment of Jakob Dupont, M.D., to its Board of Directors.